Detection of Molecular Signatures of Homologous Recombination Deficiency in Bladder Cancer
Research output: Contribution to journal › Journal article › Research › peer-review
Standard
Detection of Molecular Signatures of Homologous Recombination Deficiency in Bladder Cancer. / Börcsök, Judit; Diossy, Miklos; Sztupinszki, Zsofia; Prosz, Aurel; Tisza, Viktoria; Spisak, Sandor; Rusz, Orsolya; Stormoen, Dag Rune; Pappot, Helle; Csabai, Istvan; Brunak, Søren; Mouw, Kent W; Szallasi, Zoltan.
In: Clinical Cancer Research, Vol. 27, No. 13, 2021.Research output: Contribution to journal › Journal article › Research › peer-review
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - Detection of Molecular Signatures of Homologous Recombination Deficiency in Bladder Cancer
AU - Börcsök, Judit
AU - Diossy, Miklos
AU - Sztupinszki, Zsofia
AU - Prosz, Aurel
AU - Tisza, Viktoria
AU - Spisak, Sandor
AU - Rusz, Orsolya
AU - Stormoen, Dag Rune
AU - Pappot, Helle
AU - Csabai, Istvan
AU - Brunak, Søren
AU - Mouw, Kent W
AU - Szallasi, Zoltan
N1 - Copyright ©2021, American Association for Cancer Research.
PY - 2021
Y1 - 2021
N2 - PURPOSE: PARP inhibitors are approved for use in breast, ovarian, prostate and pancreatic cancer, which are the solid tumor types that most frequently have alterations in key homologous recombination (HR) genes, such as BRCA1/2 However, the frequency of HR deficiency in other solid tumor types, including bladder cancer, is less well characterized.EXPERIMENTAL DESIGN: Specific DNA aberration profiles (mutational signatures) are induced by homologous recombination deficiency (HRD) and the presence of these "genomic scars" can be used to assess the presence or absence of HR deficiency in a given tumor biopsy even in the absence of an observed alteration of an HR gene. Using whole exome and whole genome data, we measured various HR deficiency-associated mutational signatures in bladder cancer.RESULTS: We found that a subset of bladder tumors have evidence of HR deficiency. In addition to a small number of tumors with bi-allelic BRCA1/2 events, approximately 10% of bladder tumors had significant evidence of HR deficiency associated mutational signatures. Increased levels of HRD signatures were associated with promoter methylation of RBBP8 which encodes CtIP, a key protein involved in HR.CONCLUSION: A subset of bladder tumors have genomic features suggestive of HR deficiency and therefore may be more likely to benefit from therapies such as platinum agents and PARP inhibitors that target tumor HR deficiency.
AB - PURPOSE: PARP inhibitors are approved for use in breast, ovarian, prostate and pancreatic cancer, which are the solid tumor types that most frequently have alterations in key homologous recombination (HR) genes, such as BRCA1/2 However, the frequency of HR deficiency in other solid tumor types, including bladder cancer, is less well characterized.EXPERIMENTAL DESIGN: Specific DNA aberration profiles (mutational signatures) are induced by homologous recombination deficiency (HRD) and the presence of these "genomic scars" can be used to assess the presence or absence of HR deficiency in a given tumor biopsy even in the absence of an observed alteration of an HR gene. Using whole exome and whole genome data, we measured various HR deficiency-associated mutational signatures in bladder cancer.RESULTS: We found that a subset of bladder tumors have evidence of HR deficiency. In addition to a small number of tumors with bi-allelic BRCA1/2 events, approximately 10% of bladder tumors had significant evidence of HR deficiency associated mutational signatures. Increased levels of HRD signatures were associated with promoter methylation of RBBP8 which encodes CtIP, a key protein involved in HR.CONCLUSION: A subset of bladder tumors have genomic features suggestive of HR deficiency and therefore may be more likely to benefit from therapies such as platinum agents and PARP inhibitors that target tumor HR deficiency.
U2 - 10.1158/1078-0432.CCR-20-5037
DO - 10.1158/1078-0432.CCR-20-5037
M3 - Journal article
C2 - 33947694
VL - 27
JO - Clinical Cancer Research
JF - Clinical Cancer Research
SN - 1078-0432
IS - 13
ER -
ID: 262745088